0000000000634362

AUTHOR

Sunil V. Rao

showing 2 related works from this author

Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insight…

2020

Background: The benefits and risks of blood transfusion in patients with acute myocardial infarction who are anemic or who experience bleeding are debated. We sought to study the association between blood transfusion and ischemic outcomes according to haemoglobin nadir and bleeding status in patients with NST-elevation myocardial infarction (NSTEMI).Methods: The TAO trial randomized patients with NSTEMI and coronary angiogram scheduled within 72h to heparin plus eptifibatide versus otamixaban. After exclusion of patients who underwent coronary artery bypass surgery, patients were categorized according to transfusion status considering transfusion as a timevarying covariate. The primary isch…

medicine.medical_specialtyBlood transfusionAnemiamedicine.medical_treatmentpercutaneous coronary intervention.EptifibatideHemorrhage610 Medicine & healthpercurancous coronary intervention030204 cardiovascular system & hematologyOtamixaban11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicinelaw.invention03 medical and health sciencesCoronary artery bypass surgerychemistry.chemical_compoundPercutaneous Coronary Intervention0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumans030212 general & internal medicineMyocardial infarctionAcute Coronary SyndromeNon ST elevation Myocardial Infarction[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybusiness.industryBlood transfusionPercutaneous coronary interventionAnemiamedicine.disease3. Good healthTreatment OutcomechemistryEptifibatideCardiology and Cardiovascular Medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian …

2022

Background: Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without substantially increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of the oral FXIa inhibitor asundexian for secondary prevention after acute myocardial infarction (MI). Methods: We randomized 1601 patients with recent acute MI to oral asundexian 10, 20, or 50 mg or placebo once daily for 6 to 12 months in a double-blind, placebo-controlled, phase 2, dose-ranging trial. Patients were randomized within 5 days of their qualifying MI and received dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor. The effect of asundexian on FXIa inhibition…

MaleTicagrelorAspirinMyocardial InfarctionAnticoagulantsHemorrhageFactor XIaPercutaneous Coronary InterventionTreatment OutcomeDouble-Blind MethodPhysiology (medical)HumansFemale03.02. Klinikai orvostanAcute Coronary SyndromeCardiology and Cardiovascular MedicinePrasugrel HydrochloridePlatelet Aggregation InhibitorsAgedCirculation
researchProduct